Document Detail


Anti-IL-6-receptor antibody promotes repair of spinal cord injury by inducing microglia-dominant inflammation.
MedLine Citation:
PMID:  20478301     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We previously reported the beneficial effect of administering an anti-mouse IL-6 receptor antibody (MR16-1) immediately after spinal cord injury (SCI). The purpose of our present study was to clarify the mechanism underlying how MR16-1 improves motor function after SCI. Quantitative analyses of inflammatory cells using flow cytometry, and immunohistochemistry with bone marrow-chimeric mice generated by transplanting genetically marked purified hematopoietic stem cells, revealed that MR16-1 dramatically switched the central player in the post-traumatic inflammation, from hematogenous macrophages to resident microglia. This change was accompanied by alterations in the expression of relevant cytokines within the injured spinal cord; the expression of recruiting chemokines including CCL2, CCL5, and CXCL10 was decreased, while that of Granulocyte/Macrophage-Colony Stimulating Factor (GM-CSF), a known mitogen for microglia, was increased. We also showed that the resident microglia expressed higher levels of phagocytic markers than the hematogenous macrophages. Consistent with these findings, we observed significantly decreased tissue damage and reduced levels of myelin debris and Nogo-A, the axonal growth inhibitor, by MR16-1 treatment. Moreover, we observed increased axonal regeneration and/or sprouting in the MR16-1-treated mice. Our findings indicate that the functional improvement elicited by MR16-1 involves microglial functions, and provide new insights into the role of IL-6 signaling in the pathology of SCI.
Authors:
Masahiko Mukaino; Masaya Nakamura; Osamu Yamada; Seiji Okada; Satoru Morikawa; Francois Renault-Mihara; Akio Iwanami; Takeshi Ikegami; Yoshiyuki Ohsugi; Osahiko Tsuji; Hiroyuki Katoh; Yumi Matsuzaki; Yoshiaki Toyama; Meigen Liu; Hideyuki Okano
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-05-16
Journal Detail:
Title:  Experimental neurology     Volume:  224     ISSN:  1090-2430     ISO Abbreviation:  Exp. Neurol.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-19     Completed Date:  2010-07-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370712     Medline TA:  Exp Neurol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  403-14     Citation Subset:  IM    
Copyright Information:
(c) 2010 Elsevier Inc. All rights reserved.
Affiliation:
Department of Rehabilitation Medicine, Keio University School of Medicine, Shinjuku, Tokyo 160-8582, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Monoclonal / therapeutic use*
Chemokines / biosynthesis
Chimera
Female
Granulocyte-Macrophage Colony-Stimulating Factor / metabolism
Hematopoietic Stem Cell Transplantation
Inflammation / immunology
Macrophages / drug effects,  immunology
Mice
Mice, Transgenic
Microglia / drug effects*,  immunology
Phagocytosis
Rats
Receptors, Interleukin-6 / immunology*
Spinal Cord / drug effects,  immunology,  pathology
Spinal Cord Injuries / drug therapy*,  immunology,  pathology
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Chemokines; 0/Receptors, Interleukin-6; 83869-56-1/Granulocyte-Macrophage Colony-Stimulating Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Analysis of early human neural crest development.
Next Document:  Drug interaction between celecoxib and methotrexate in organic anion transporter 3-transfected renal...